Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin / ESMO

esmo - Findings from the KEYNOTE-905/EV-303 study

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology

Blood test predicts which bladder cancer patients may safely skip surgery

11 days / medicalxpress

Perioperative enfortumab vedotin + pembrolizumab tied to improved outcomes with bladder cancer

11 days / medicalxpress

Padcev-Keytruda combo delivers more positive data in bladder cancer

12 days / endpoints / Max Gelman

Neeraj Agarwal on ASCO GU 2026: Survival Signals, Biomarkers and the Future of GU Trials Part 2

12 days / oncodaily

Javier Molina Cerrillo: Liver Metastases in Advanced UC – Does Immunotherapy Make a Difference?

13 days / oncodaily

Shilpa Gupta: Latest Advances in Bladder Cancer at ASCO GU 2026

13 days / oncodaily

10 Must-Read Posts in Immuno-Oncology This Week

14 days / oncodaily

ASCO GU 2026: 10 Most Promising Trials Shaping the Future of Genitourinary Oncology

14 days / oncodaily

Ahmet Dirican: MIBC Staging Is No Longer Just Anatomical

14 days / oncodaily

Muharrem Coşkunpınar: Expanding Perspectives in Metastatic Bladder and Kidney Cancer Care

15 days / oncodaily

Recipients of the Conquer Cancer 2026 Genitourinary Cancers Symposium Merit Awards

15 days / oncodaily

Andrea Necchi: Multidisciplinary Effoert Needed for Treating Variant Histologies of Bladder Cancer

15 days / oncodaily

Shilpa Gupta: Grateful to ASCO For the Opportunity to Serve as ASCOGU26 Featured Voice

16 days / oncodaily

Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin

16 days / esmo

Jad Chahoud Celebrates Nabil Adra Advancing Pembrolizumab-EV in Bladder Cancer

18 days / oncodaily

Monday, February 23, 2026, 2:22 am / permalink 19558 / 15 stories in 16 days

Related Stories

Related Tags

Healthcare

Judge orders Leapfrog to remove safety grades for five Florida hospitals (21 hrs)

Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (40 hrs)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

more #healthcare

Pharmaceuticals

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity (2 days)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)

more #pharmaceuticals

Biotech

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity (2 days)

Cancer Grand Challenges awards five teams bold funding for cancer research (3 days)

Belzutifan combinations highlighted at ASCO GU improve RCC outcomes (4 days)

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.